Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMODA2X)

• Drug Name: Bardoxolone methyl Drug Info
• Synonyms: BARD; WPTTVJLTNAWYAO-OYWPANLISA-N; 218600-53-4

Indication

Disease Entry	ICD 11	Status	REF
Mixed connective tissue disease	4A43.3	Phase 3	[1]
Pulmonary arterial hypertension	BB01.0	Phase 2	[2]
Pulmonary hypertension	BB01	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 400769
  ChEBI ID: CHEMBL1762621
  CAS Number: CAS 218600-53-4
  TTD Drug ID: DMODA2X
  VARIDT Drug ID: DR00793

Molecule-Related Drug Atlas

Drug(s) Targeting PPAR-gamma messenger RNA (PPARG mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AD-5075	DM1SLJ9	Type-2 diabetes	5A11	Terminated	[8]
2-chloro-5-nitro-N-phenylbenzamide	DMUGQIV	Discovery agent	N.A.	Investigative	[9]
L-783483	DM6OTGE	Discovery agent	N.A.	Investigative	[10]
LG100754	DMEK4FY	Discovery agent	N.A.	Investigative	[11]
L-796449	DMWTGQM	Discovery agent	N.A.	Investigative	[12]
L-165461	DMKBSGN	Discovery agent	N.A.	Investigative	[12]
AD-5061	DM5WV13	Discovery agent	N.A.	Investigative	[13]
TZD18	DMVCHOX	Discovery agent	N.A.	Investigative	[14]
(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid	DM2REIN	Discovery agent	N.A.	Investigative	[15]
reglitazar	DMQ3ER0	Discovery agent	N.A.	Investigative	[16]

Drug(s) Affected By D(2) dopamine receptor (DRD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Droperidol	DM0DXA8	Nausea	MD90	Approved	[17]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[17]
Zuclopenthixol	DMKYD5N	Schizophrenia	6A20	Approved	[17]
Meglitinides	DM1OFHN	Type-2 diabetes	5A11	Approved	[18]
Sulpiride	DMF54ZG	Schizophrenia	6A20	Approved	[19]
Risperidone	DMN6DXL	Bipolar I disorder		Approved	[20]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[21]
Methamphetamine	DMPM4SK	Anxiety		Approved	[22]
Bromocriptine	DMVE3TK	Acromegaly	5A60.0	Approved	[23]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[24]

Drug(s) Affected By Alpha-2C adrenergic receptor (ADRA2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[25]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[26]
Oxymetazoline	DM8ZXT6	Arrhythmia	BC9Z	Approved	[27]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[29]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[31]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[32]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[33]
Xylometazoline	DMKV32D	Allergic rhinitis	CA08.0	Phase 4	[27]

Drug(s) Affected By D(1A) dopamine receptor (DRD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[17]
Haloperidol	DM96SE0	Delirium		Approved	[34]
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[35]
Pergolide mesylate	DM5GKOV	N. A.	N. A.	Approved	[36]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[34]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[38]
Methamphetamine	DMPM4SK	Anxiety		Approved	[39]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[40]

Drug(s) Affected By 5-hydroxytryptamine receptor 2A (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[17]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[24]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[41]
Haloperidol	DM96SE0	Delirium		Approved	[41]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[42]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[43]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[44]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[45]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[46]

Drug(s) Affected By 5-hydroxytryptamine receptor 2C (HTR2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[47]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[47]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[47]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[49]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[50]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[51]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]

Drug(s) Affected By Alpha-1B adrenergic receptor (ADRA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[54]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[55]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[26]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[51]
Oxymetazoline	DM8ZXT6	Arrhythmia	BC9Z	Approved	[27]
Terbutaline	DMD4381	Asthma	CA23	Approved	[56]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[54]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[56]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[57]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[45]

Drug(s) Affected By Mu-type opioid receptor (OPRM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alvimopan	DMHR8KW	Gastrointestinal disease	DE2Z	Approved	[58]
Fentanyl	DM8WAHT	Analgesia	MB40.8	Approved	[59]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[60]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[62]
Butorphanol	DM5KYPJ	Pain	MG30-MG3Z	Approved	[63]
Oliceridine	DM6MDCF	Acute pain	MG31	Approved	[59]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[64]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[65]

Drug(s) Affected By Kappa-type opioid receptor (OPRK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[67]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[68]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[69]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[70]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[67]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[71]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[17]

Drug(s) Affected By 3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[73]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[74]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[75]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[51]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[77]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[78]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[79]

Drug(s) Affected By Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[80]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[61]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[81]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[82]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[83]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[84]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[45]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[85]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[86]

Drug(s) Affected By NF-kappa-B inhibitor epsilon (NFKBIE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[87]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[88]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[90]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[91]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[92]
Bortezomib	DMNO38U	Leukemia		Approved	[93]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[94]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[87]

Drug(s) Affected By Transcription factor MafG (MAFG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[95]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[97]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[98]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[99]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[100]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[101]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]

Drug(s) Affected By SH3 domain-binding protein 5 (SH3BP5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[102]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[103]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[104]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[52]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[105]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[106]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[107]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[108]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[109]

Drug(s) Affected By Dynamin-like 120 kDa protein, mitochondrial (OPA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[110]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Selenium	DM25CGV	N. A.	N. A.	Approved	[25]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[112]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[113]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[92]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[114]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[115]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[116]

Drug(s) Affected By Mitofusin-2 (MFN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[102]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[113]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[117]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[92]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[118]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[116]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[119]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[85]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[120]

Drug(s) Affected By Annexin A1 (ANXA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[121]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[122]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[26]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[67]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[123]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[74]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[124]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[125]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[122]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]

Drug(s) Affected By Amino acid transporter heavy chain SLC3A2 (SLC3A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[25]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[126]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[97]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[127]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[128]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[129]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[130]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[129]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[131]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[100]

Drug(s) Affected By ATP-dependent 6-phosphofructokinase, muscle type (PFKM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[132]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[92]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[133]
Clotrimazole	DMMFCIH	Cutaneous candidiasis	1F23.14	Approved	[132]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[134]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[85]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[135]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[136]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[137]

Drug(s) Affected By Growth-regulated alpha protein (CXCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[138]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[139]
Selenium	DM25CGV	N. A.	N. A.	Approved	[140]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[61]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[122]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[127]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[141]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[142]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[141]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[143]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[138]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[144]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[145]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[146]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[147]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[148]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[147]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[149]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[150]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[151]

Drug(s) Affected By C-C motif chemokine 2 (CCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[152]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[153]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[154]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[155]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[156]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[157]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[158]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[66]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[159]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[160]

Drug(s) Affected By Beta-1,4-galactosyltransferase 1 (B4GALT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[161]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[51]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[92]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[29]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[162]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[162]
Estriol	DMOEM2I	Hormone deficiency	5A61.1	Approved	[162]

Drug(s) Affected By Glutathione peroxidase 2 (GPX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[95]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[163]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[97]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[164]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[165]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[166]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[167]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[98]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[74]

Drug(s) Affected By Tumor necrosis factor alpha-induced protein 3 (TNFAIP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[168]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[138]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[88]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[127]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[168]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[5]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[169]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[170]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[168]

Drug(s) Affected By Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[172]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[173]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[174]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[126]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[175]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[176]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[177]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[178]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[179]

Drug(s) Affected By DnaJ homolog subfamily B member 1 (DNAJB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[180]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[181]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[129]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[130]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[98]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[182]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[183]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[184]

Drug(s) Affected By DNA damage-inducible transcript 3 protein (DDIT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Triacetin	DM0AEPG	Onychomycosis	EE12.1	Approved	[185]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[172]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[186]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[187]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[188]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[189]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[190]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[97]

Drug(s) Affected By Lon protease homolog, mitochondrial (LONP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[191]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[191]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[192]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[113]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[193]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[42]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[57]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[87]

Drug(s) Affected By Small ribosomal subunit protein eS6 (RPS6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[194]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[61]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[195]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[196]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[197]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[198]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[199]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[200]
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[201]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]

Drug(s) Affected By Oxidized low-density lipoprotein receptor 1 (OLR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[202]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[202]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[203]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[51]
Aldosterone	DM9S2JW	Hypertension	BA00-BA04	Approved	[204]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[205]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[206]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[202]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[202]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[207]

Drug(s) Affected By C-C motif chemokine 20 (CCL20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[138]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[208]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[139]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[142]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[127]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[209]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[142]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[51]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[99]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[210]

Drug(s) Affected By Heat shock factor protein 1 (HSF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[211]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[212]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[212]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[213]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[214]
Ceftazidime	DM41GRA	Bacteremia	1A73	Approved	[212]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[212]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[212]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[212]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 9 (TNFRSF9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[202]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[215]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[216]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[217]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[218]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[219]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 3 (BIRC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[220]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[221]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[80]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[146]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[222]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[164]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[129]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[223]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[170]

Drug(s) Affected By Kelch-like ECH-associated protein 1 (KEAP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[224]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[225]
Selenium	DM25CGV	N. A.	N. A.	Approved	[25]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[226]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[227]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[100]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[100]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[100]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[228]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[91]

Drug(s) Affected By Neutral amino acid transporter B(0) (SLC1A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[229]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[100]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[100]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[100]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[92]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[229]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[100]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[229]

Drug(s) Affected By Mitofusin-1 (MFN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[230]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[97]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[99]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[114]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[118]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[231]
Bortezomib	DMNO38U	Leukemia		Approved	[232]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]

Drug(s) Affected By Thyroid hormone-inducible hepatic protein (THRSP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[165]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[233]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[165]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[165]
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[234]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[30]
Mitotane	DMU1GX0	Adrenocortical carcinoma	2D11.Z	Approved	[234]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[116]

Drug(s) Affected By Multidrug and toxin extrusion protein 1 (SLC47A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[235]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[236]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[237]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[236]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[66]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[238]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[239]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[77]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[236]

Drug(s) Affected By Bcl-2-binding component 3, isoforms 3/4 (BBC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[87]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[146]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[126]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[240]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[241]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[242]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[243]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[244]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[245]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[246]

Drug(s) Affected By Tribbles homolog 3 (TRIB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[165]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[26]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[129]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[130]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[247]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[129]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[74]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[183]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[131]

Drug(s) Affected By Sulfiredoxin-1 (SRXN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[95]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[87]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[127]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[248]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[5]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[129]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[100]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[99]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[100]

Drug(s) Affected By Prolyl hydroxylase EGLN3 (EGLN3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[112]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[28]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[120]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[57]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[249]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[52]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[85]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[33]

Drug(s) Affected By 5'-AMP-activated protein kinase subunit gamma-2 (PRKAG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[103]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[92]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[29]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[45]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[250]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[251]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[85]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PPAR-gamma messenger RNA (PPARG mRNA)	TTT2SVW	PPARG_HUMAN	Antagonist	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B)	OTOA8WU2	PDE4B_HUMAN	Gene/Protein Processing	[4]
5'-AMP-activated protein kinase subunit gamma-2 (PRKAG2)	OTHTAM54	AAKG2_HUMAN	Gene/Protein Processing	[5]
5-hydroxytryptamine receptor 2A (HTR2A)	OTWXJX0M	5HT2A_HUMAN	Gene/Protein Processing	[4]
5-hydroxytryptamine receptor 2C (HTR2C)	OT6H8DE0	5HT2C_HUMAN	Gene/Protein Processing	[4]
Alpha-1B adrenergic receptor (ADRA1B)	OTSAYAFD	ADA1B_HUMAN	Gene/Protein Processing	[4]
Alpha-2C adrenergic receptor (ADRA2C)	OT5B9RKP	ADA2C_HUMAN	Gene/Protein Processing	[4]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Gene/Protein Processing	[5]
AN1-type zinc finger protein 2A	OTTG7P8R	ZFN2A_HUMAN	Gene/Protein Processing	[5]
Annexin A1 (ANXA1)	OT5OFDJC	ANXA1_HUMAN	Gene/Protein Processing	[6]
ATP-dependent 6-phosphofructokinase, muscle type (PFKM)	OT1QY9JM	PFKAM_HUMAN	Gene/Protein Processing	[7]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol. 2000 Oct;14(10):1550-6.
• [4] Characterization of the potent, selective Nrf2 activator, 3-(pyridin-3-ylsulfonyl)-5-(trifluoromethyl)-2H-chromen-2-one, in cellular and in vivo models of pulmonary oxidative stress. J Pharmacol Exp Ther. 2017 Oct;363(1):114-125.
• [5] Mapping the dynamics of Nrf2 antioxidant and NFB inflammatory responses by soft electrophilic chemicals in human liver cells defines the transition from adaptive to adverse responses. Toxicol In Vitro. 2022 Oct;84:105419. doi: 10.1016/j.tiv.2022.105419. Epub 2022 Jun 17.
• [6] Fluorescent tagging of endogenous Heme oxygenase-1 in human induced pluripotent stem cells for high content imaging of oxidative stress in various differentiated lineages. Arch Toxicol. 2021 Oct;95(10):3285-3302. doi: 10.1007/s00204-021-03127-8. Epub 2021 Sep 4.
• [7] Synthetic oleanane triterpenoid derivative CDDO-Me disrupts cellular bioenergetics to suppress pancreatic ductal adenocarcinoma via targeting SLC1A5. J Biochem Mol Toxicol. 2022 Nov;36(11):e23192. doi: 10.1002/jbt.23192. Epub 2022 Aug 5.
• [8] Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996 Oct;137(10):4189-95.
• [9] Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
• [10] Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25.
• [11] The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem. 2002 Apr 12;277(15):12503-6.
• [12] Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
• [13] A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
• [14] A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8.
• [15] Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
• [16] Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9.
• [17] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [18] Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008 Apr;197(2):229-35. doi: 10.1007/s00213-007-1029-z. Epub 2007 Dec 6.
• [19] Positron emission tomography measurement of dopamine D? receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010 Sep;71(9):1131-7. doi: 10.4088/JCP.08m04307yel. Epub 2010 Feb 23.
• [20] Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009 May;19(5):373-82. doi: 10.1097/FPC.0b013e328329a60f.
• [21] Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010 Jun;20(6):359-66. doi: 10.1097/FPC.0b013e3283397d06.
• [22] A preliminary study: novelty seeking, frontal executive function, and dopamine receptor (D2) TaqI A gene polymorphism in patients with methamphetamine dependence. Compr Psychiatry. 2008 Jul-Aug;49(4):387-92. doi: 10.1016/j.comppsych.2008.01.008. Epub 2008 Mar 21.
• [23] Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett. 2006 Sep 25;405(3):196-201. doi: 10.1016/j.neulet.2006.07.030. Epub 2006 Aug 8.
• [24] Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
• [25] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [26] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [27] Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
• [28] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [29] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [30] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [31] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [32] Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis. Biol Reprod. 2011 Apr;84(4):801-15.
• [33] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [34] Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95.
• [35] Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992 Jul;49(7):538-44. doi: 10.1001/archpsyc.1992.01820070032005.
• [36] Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction. Circulation. 2005 Sep 6;112(10):1494-9. doi: 10.1161/CIRCULATIONAHA.105.556704. Epub 2005 Aug 29.
• [37] Dopamine-mediated inhibition of renal Na+/K+-ATPase in HK-2 cells is reduced by ouabain. Clin Exp Pharmacol Physiol. 2010 May;37(5-6):613-8. doi: 10.1111/j.1440-1681.2010.05364.x. Epub 2010 Feb 4.
• [38] Characterizing fucoxanthin as a selective dopamine D(3)/D(4) receptor agonist: Relevance to Parkinson's disease. Chem Biol Interact. 2019 Sep 1;310:108757. doi: 10.1016/j.cbi.2019.108757. Epub 2019 Jul 16.
• [39] Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users. Mol Psychiatry. 2000 Nov;5(6):664-72. doi: 10.1038/sj.mp.4000760.
• [40] Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol. 2007 Sep;21(7):718-27. doi: 10.1177/0269881106072341. Epub 2006 Nov 8.
• [41] Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.
• [42] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [43] No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
• [44] Nephrotoxicity induced by cisplatin is primarily due to the activation of the 5-hydroxytryptamine degradation system in proximal renal tubules. Chem Biol Interact. 2021 Nov 1;349:109662. doi: 10.1016/j.cbi.2021.109662. Epub 2021 Sep 21.
• [45] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [46] Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011 Jul;26(7):1813-25.
• [47] Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
• [48] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [49] Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clin Neuropharmacol. 1993;16 Suppl 3:S19-31.
• [50] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [51] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [52] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [53] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [54] Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. doi: 10.1161/01.cir.97.13.1227.
• [55] Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. doi: 10.1016/j.cardiores.2004.05.014.
• [56] Neuroendocrine mediators up-regulate alpha1b- and alpha1d-adrenergic receptor subtypes in human monocytes. J Neuroimmunol. 1999 Mar 1;95(1-2):165-73. doi: 10.1016/s0165-5728(99)00011-9.
• [57] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [58] The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn Schmiedebergs Arch Pharmacol. 2007 May;375(3):205-20. doi: 10.1007/s00210-007-0146-x. Epub 2007 Mar 6.
• [59] A G protein-biased ligand at the ?-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013 Mar;344(3):708-17.
• [60] Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008 Apr;83(4):559-66.
• [61] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [62] The effect of mitragynine on cAMP formation and mRNA expression of mu-opioid receptors mediated by chronic morphine treatment in SK-N-SH neuroblastoma cell. J Ethnopharmacol. 2013 Jun 21;148(1):135-43. doi: 10.1016/j.jep.2013.03.078. Epub 2013 Apr 19.
• [63] In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances. Arch Toxicol. 2020 Nov;94(11):3819-3830. doi: 10.1007/s00204-020-02855-7. Epub 2020 Jul 31.
• [64] Cannabinoid receptor type 2 agonists induce transcription of the mu-opioid receptor gene in Jurkat T cells. Mol Pharmacol. 2006 Apr;69(4):1486-91. doi: 10.1124/mol.105.018325. Epub 2006 Jan 24.
• [65] Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2'-deoxycytidine. Neuroimmunomodulation. 2012;19(3):180-6. doi: 10.1159/000331474. Epub 2012 Jan 18.
• [66] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [67] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [68] The role of acetaldehyde in mediating effects of alcohol on expression of endogenous opioid system genes in a neuroblastoma cell line. FASEB J. 2008 Mar;22(3):662-70. doi: 10.1096/fj.07-8346com. Epub 2007 Oct 12.
• [69] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [70] In vivo and in vitro evaluation of novel -opioid receptor agonist compounds. Eur J Pharmacol. 2015 Nov 15;767:193-200. doi: 10.1016/j.ejphar.2015.10.025. Epub 2015 Oct 20.
• [71] Effects of tobacco compounds on gene expression in fetal lung fibroblasts. Environ Toxicol. 2008 Aug;23(4):423-34.
• [72] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [73] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [74] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [75] Histamine up-regulates phosphodiesterase 4 activity and reduces prostaglandin E2-inhibitory effects in human neutrophils. Inflamm Res. 2000 Nov;49(11):600-9. doi: 10.1007/s000110050637.
• [76] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [77] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [78] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [79] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [80] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [81] Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
• [82] Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2016 Apr 1;296:42-53. doi: 10.1016/j.taap.2016.01.015. Epub 2016 Jan 25.
• [83] Modulation of the heart's electrical properties by the anticonvulsant drug retigabine. Toxicol Appl Pharmacol. 2017 Aug 15;329:309-317. doi: 10.1016/j.taap.2017.06.018. Epub 2017 Jun 20.
• [84] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [85] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [86] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [87] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [88] Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
• [89] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [90] Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet. 2010 Jun;199(2):110-20. doi: 10.1016/j.cancergencyto.2010.02.010.
• [91] A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013 Feb;13(1):94-104. doi: 10.1038/tpj.2011.48. Epub 2011 Nov 15.
• [92] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [93] Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene. 2005 Jan 13;24(3):419-30. doi: 10.1038/sj.onc.1208212.
• [94] Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
• [95] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [96] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [97] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [98] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [99] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [100] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [101] Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
• [102] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [103] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [104] Gene expression data from acetaminophen-induced toxicity in human hepatic in vitro systems and clinical liver samples. Data Brief. 2016 Mar 26;7:1052-1057. doi: 10.1016/j.dib.2016.03.069. eCollection 2016 Jun.
• [105] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [106] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [107] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [108] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [109] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [110] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [111] Tea polyphenols direct Bmal1-driven ameliorating of the redox imbalance and mitochondrial dysfunction in hepatocytes. Food Chem Toxicol. 2018 Dec;122:181-193.
• [112] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [113] Lon protease: a novel mitochondrial matrix protein in the interconnection between drug-induced mitochondrial dysfunction and endoplasmic reticulum stress. Br J Pharmacol. 2017 Dec;174(23):4409-4429. doi: 10.1111/bph.14045. Epub 2017 Nov 7.
• [114] Protective effects of silibinin against ethanol- or acetaldehyde-caused damage in liver cell lines involve the repression of mitochondrial fission. Toxicol In Vitro. 2022 Apr;80:105330. doi: 10.1016/j.tiv.2022.105330. Epub 2022 Feb 11.
• [115] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [116] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [117] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [118] Melatonin prevents blood-retinal barrier breakdown and mitochondrial dysfunction in high glucose and hypoxia-induced in vitro diabetic macular edema model. Toxicol In Vitro. 2021 Sep;75:105191. doi: 10.1016/j.tiv.2021.105191. Epub 2021 May 5.
• [119] 5-Fluorouracil inhibits neural differentiation via Mfn1/2 reduction in human induced pluripotent stem cells. J Toxicol Sci. 2018;43(12):727-734. doi: 10.2131/jts.43.727.
• [120] Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
• [121] Protein expression profiling identifies molecular targets of quercetin as a major dietary flavonoid in human colon cancer cells. Proteomics. 2004 Jul;4(7):2160-74.
• [122] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [123] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [124] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [125] Proteomics analysis of the proliferative effect of low-dose ouabain on human endothelial cells. Biol Pharm Bull. 2007 Feb;30(2):247-53. doi: 10.1248/bpb.30.247.
• [126] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [127] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [128] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [129] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [130] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [131] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [132] Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact. 2015 May 25;233:147-56. doi: 10.1016/j.cbi.2015.03.028. Epub 2015 Apr 8.
• [133] Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12.
• [134] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [135] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [136] Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie. 2013 Jun;95(6):1336-43. doi: 10.1016/j.biochi.2013.02.013. Epub 2013 Feb 27.
• [137] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [138] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [139] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [140] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [141] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [142] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [143] Zinc induces chemokine and inflammatory cytokine release from human promonocytes. J Hazard Mater. 2011 Nov 30;196:335-41. doi: 10.1016/j.jhazmat.2011.09.035. Epub 2011 Sep 19.
• [144] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [145] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [146] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [147] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [148] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [149] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [150] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [151] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [152] Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
• [153] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [154] Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib. Toxicol Lett. 2021 Mar 1;338:1-9. doi: 10.1016/j.toxlet.2020.11.011. Epub 2020 Nov 25.
• [155] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [156] Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
• [157] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [158] Dimethyl Fumarate Inhibits the Nuclear Factor B Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem. 2016 Feb 12;291(7):3639-47. doi: 10.1074/jbc.M115.679704. Epub 2015 Dec 18.
• [159] Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc.
• [160] Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NFB and AhR and EGFR-ERK pathway. Toxicol Appl Pharmacol. 2011 Sep 1;255(2):138-49.
• [161] Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004 Oct;25(10):1327-33.
• [162] Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol. 2004 Feb;18(2):402-11. doi: 10.1210/me.2003-0202. Epub 2003 Nov 6.
• [163] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [164] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [165] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [166] Retinoic acid induces Gpx2 gene expression in MCF-7 human breast cancer cells. J Nutr. 1999 Oct;129(10):1846-54. doi: 10.1093/jn/129.10.1846.
• [167] Expression of gastrointestinal glutathione peroxidase is inversely correlated to the presence of hepatitis C virus subgenomic RNA in human liver cells. J Biol Chem. 2005 Mar 11;280(10):8831-41. doi: 10.1074/jbc.M413730200. Epub 2004 Dec 28.
• [168] Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci. 2011 Dec;124(2):278-90. doi: 10.1093/toxsci/kfr225. Epub 2011 Aug 27.
• [169] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [170] The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915. doi: 10.1016/j.taap.2020.114915. Epub 2020 Feb 6.
• [171] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [172] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [173] Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
• [174] Chromium III histidinate exposure modulates gene expression in HaCaT human keratinocytes exposed to oxidative stress. Biol Trace Elem Res. 2010 Oct;137(1):23-39.
• [175] A dual role of p21waf1/cip1 gene in apoptosis of HEp-2 treated with cisplatin or methotrexate. Cancer Gene Ther. 2008 Sep;15(9):576-90. doi: 10.1038/cgt.2008.28. Epub 2008 May 16.
• [176] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [177] Quercetin and Its Fermented Extract as a Potential Inhibitor of Bisphenol A-Exposed HT-29 Colon Cancer Cells' Viability. Int J Mol Sci. 2023 Mar 15;24(6):5604. doi: 10.3390/ijms24065604.
• [178] The Effect of GADD45a on Furazolidone-Induced S-Phase Cell-Cycle Arrest in Human Hepatoma G2 Cells. J Biochem Mol Toxicol. 2015 Oct;29(10):489-495. doi: 10.1002/jbt.21719. Epub 2015 Jun 11.
• [179] Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene. 2004 Jun 3;23(26):4614-23. doi: 10.1038/sj.onc.1207598.
• [180] Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther. 2009 May;8(5):1197-206.
• [181] Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
• [182] Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3767-77.
• [183] Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis. 2010 Jun 2;9:56. doi: 10.1186/1476-511X-9-56.
• [184] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [185] Induction of CCAAT/enhancer-binding protein-homologous protein by cigarette smoke through the superoxide anion-triggered PERK-eIF2 pathway. Toxicology. 2011 Sep 5;287(1-3):105-12. doi: 10.1016/j.tox.2011.06.005. Epub 2011 Jun 15.
• [186] Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
• [187] Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
• [188] High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol. 2017 Mar;91(3):1367-1383. doi: 10.1007/s00204-016-1781-0. Epub 2016 Jun 29.
• [189] Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicol Sci. 2014 Jan;137(1):234-48. doi: 10.1093/toxsci/kft232. Epub 2013 Oct 17.
• [190] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [191] Lon protease and eiF2 are involved in acute, but not prolonged, antiretroviral induced stress response in HepG2 cells. Chem Biol Interact. 2016 May 25;252:82-6. doi: 10.1016/j.cbi.2016.03.021. Epub 2016 Apr 1.
• [192] Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
• [193] Antihypertrophic Effects of Small Molecules that Maintain Mitochondrial ATP Levels Under Hypoxia. EBioMedicine. 2017 Oct;24:147-158. doi: 10.1016/j.ebiom.2017.09.022. Epub 2017 Sep 19.
• [194] Cannabidiol Reduces Leukemic Cell Size - But Is It Important?. Front Pharmacol. 2017 Mar 24;8:144. doi: 10.3389/fphar.2017.00144. eCollection 2017.
• [195] Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011 Dec;78(6):999-1005. doi: 10.1111/j.1747-0285.2011.01239.x. Epub 2011 Oct 31.
• [196] D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2009 Apr 24;382(1):96-101. doi: 10.1016/j.bbrc.2009.02.129. Epub 2009 Feb 28.
• [197] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [198] Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. Aging (Albany NY). 2012 Dec;4(12):952-65. doi: 10.18632/aging.100521.
• [199] Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res. 2010 Oct;30(10):3895-901.
• [200] Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
• [201] Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene. 2016 Aug 25;35(34):4518-28. doi: 10.1038/onc.2015.511. Epub 2016 Feb 8.
• [202] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [203] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [204] Aldosterone augments LOX-1-mediated low-density lipoprotein uptake in human umbilical artery endothelial cells. Pharmacol Rep. 2010 Mar-Apr;62(2):311-8. doi: 10.1016/s1734-1140(10)70271-1.
• [205] PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
• [206] Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
• [207] Nifedipine prevents apoptosis of endothelial cells induced by oxidized low-density lipoproteins. J Cardiovasc Pharmacol. 2002 Jul;40(1):146-52. doi: 10.1097/00005344-200207000-00018.
• [208] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [209] Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood. 2009 Dec 24;114(27):5512-21. doi: 10.1182/blood-2009-02-204834. Epub 2009 Oct 14.
• [210] Mechanical stress-activated immune response genes via Sirtuin 1 expression in human periodontal ligament cells. Clin Exp Immunol. 2012 Apr;168(1):113-24. doi: 10.1111/j.1365-2249.2011.04549.x.
• [211] NRF2 transcriptionally activates the heat shock factor 1 promoter under oxidative stress and affects survival and migration potential of MCF7 cells. J Biol Chem. 2018 Dec 14;293(50):19303-19316. doi: 10.1074/jbc.RA118.003376. Epub 2018 Oct 11.
• [212] A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
• [213] Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999 May;11(5):347-58. doi: 10.1006/cyto.1998.0437.
• [214] Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis. 2006 Oct;188(2):265-73. doi: 10.1016/j.atherosclerosis.2005.10.045. Epub 2005 Dec 20.
• [215] Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia. Int J Oncol. 2005 Aug;27(2):537-45.
• [216] Effect of chemical mutagens and carcinogens on gene expression profiles in human TK6 cells. PLoS One. 2012;7(6):e39205. doi: 10.1371/journal.pone.0039205. Epub 2012 Jun 18.
• [217] 2,3,7,8-tetrachlorodibenzo-p-dioxin augments the modulation of gene expression mediated by the thyroid hormone receptor. Toxicol Appl Pharmacol. 2004 Feb 1;194(3):201-10. doi: 10.1016/j.taap.2003.09.010.
• [218] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [219] Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol. 2009 Mar;144(5):667-76. doi: 10.1111/j.1365-2141.2008.07504.x. Epub 2008 Nov 20.
• [220] Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004 Jan;3(1):71-84.
• [221] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [222] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [223] Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 2010 Sep;27(3):833-42. doi: 10.1007/s12032-009-9294-9. Epub 2009 Sep 10.
• [224] Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2016 Nov 1;310:140-149. doi: 10.1016/j.taap.2016.09.010. Epub 2016 Sep 14.
• [225] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [226] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [227] Hydroquinone triggers pyroptosis and endoplasmic reticulum stress via AhR-regulated oxidative stress in human lymphocytes. Toxicol Lett. 2023 Mar 1;376:39-50. doi: 10.1016/j.toxlet.2023.01.005. Epub 2023 Jan 13.
• [228] Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. Chem Res Toxicol. 2015 Oct 19;28(10):1903-13. doi: 10.1021/acs.chemrestox.5b00105. Epub 2015 Sep 21.
• [229] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [230] Tea polyphenols ameliorates neural redox imbalance and mitochondrial dysfunction via mechanisms linking the key circadian regular Bmal1. Food Chem Toxicol. 2017 Dec;110:189-199. doi: 10.1016/j.fct.2017.10.031. Epub 2017 Oct 20.
• [231] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [232] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [233] Activated thyroid hormone receptor modulates dioxin-inducible aryl hydrocarbon receptor-mediated CYP1A1 induction in human hepatocytes but not in human hepatocarcinoma HepG2 cells. Toxicol Lett. 2017 Jun 5;275:77-82.
• [234] Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
• [235] Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid. Chem Biol Interact. 2020 Jun 1;324:109097. doi: 10.1016/j.cbi.2020.109097. Epub 2020 Apr 16.
• [236] Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab Dispos. 2006 Nov;34(11):1868-74. doi: 10.1124/dmd.106.010876. Epub 2006 Aug 23.
• [237] Neonicotinoid pesticides poorly interact with human drug transporters. J Biochem Mol Toxicol. 2019 Oct;33(10):e22379. doi: 10.1002/jbt.22379. Epub 2019 Jul 31.
• [238] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [239] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [240] Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
• [241] Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes. Anticancer Drugs. 2007 Aug;18(7):763-72. doi: 10.1097/CAD.0b013e3280adc905.
• [242] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [243] D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis. 2012 Oct;17(10):1079-94.
• [244] Involvement of mitochondrial dysfunction in nefazodone-induced hepatotoxicity. Food Chem Toxicol. 2016 Aug;94:148-58. doi: 10.1016/j.fct.2016.06.001. Epub 2016 Jun 8.
• [245] Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment. J Pharmacol Exp Ther. 2014 Mar;348(3):360-71. doi: 10.1124/jpet.113.210054. Epub 2013 Dec 17.
• [246] Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis. 2010 Feb;15(2):219-29. doi: 10.1007/s10495-009-0424-9.
• [247] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [248] Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
• [249] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [250] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [251] Progesterone regulation of implantation-related genes: new insights into the role of oestrogen. Cell Mol Life Sci. 2007 Apr;64(7-8):1009-32.